Articles

In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission with nilotinib in patients with chronic-phase chronic myeloid leukemia (CP-CML).

Philanthropic individuals can contribute a wide variety of assets to charity. In addition to the social good that comes with the contribution, there may also be a financial benefit to the donor through an income tax charitable deduction for the charitable gift. However, the one asset that is often overlooked when it comes to charitable contributions is life insurance.

Although there have been several trial-based studies on the use of ruxolitinib in patients with lower-risk myelofibrosis (MF), Keith L. Davis, MA, Senior Director of Health Economics at RTI Health Solutions and colleagues sought to conduct a study in the real-world setting.

IDH mutations have been observed among various groups of patients, including those with glioblastoma multiforme, grade 2 and 3 gliomas, and secondary glioblastomas, as well as patients with acute myeloid leukemia. However, limited data exist among patients with Philadelphia-negative myeloproliferative neoplasms.

With recent evidence pointing to a link between chronic inflammation and Philadelphia-negative myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, and myelofibrosis, Hans Carl Hasselbalch, MD, DMSc, and Mads Emil Bjorn, MD, PhDc, Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark, recently published a review article purporting that myeloproliferative neoplasms are inflammatory diseases.

Great advances have been made in our understanding of how myeloproliferative neoplasms (MPNs)–essential thrombocythemia, polycythemia vera, myelofibrosis (MF)–result in overproduction of inflammatory markers, according to Holly L. Geyer, MD, Assistant Professor of Medicine, Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ, and colleagues.

Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.

Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner.

Succeeding in today’s crowded healthcare market often requires that associations align with like-minded organizations to achieve their goals. It is this realization that has led to a strategic partnership between The Lynx Group and the National Association of Specialty Pharmacy (NASP).